Shilpa Kuttikrishnan
Doha, DA, Qatar
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Pristimerin drives ROS-dependent apoptosis in cutaneous T-cell lymphoma via inhibition of the AKT-SKP2 axis.
Journal: Toxicology and applied pharmacology
Published: February 05, 2026
Pristimerin drives ROS-dependent apoptosis in cutaneous T-cell lymphoma via inhibition of the AKT-SKP2 axis.
Journal: Toxicology and applied pharmacology
Published: February 05, 2026
Selective induction of apoptosis in T-cell acute lymphoblastic leukemia by pristimerin through dual PI3K/AKT pathway inhibition and ROS generation.
Journal: European journal of pharmacology
Published: June 25, 2025
Sanguinarine Induces ROS-Mediated Mitochondrial Dysfunction and Inhibits AKT/GSK3 Signaling to Potentiate Apoptotic Effects in Cutaneous T-Cell Lymphoma.
Journal: Phytotherapy research : PTR
Published: March 28, 2025
PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: March 13, 2025
Curcumin induces apoptosis via downregulation of SKP2 and induction of GADD45A/CDKN1A expression through generation of ROS in cutaneous T-cell lymphoma cells.
Journal: Toxicology and applied pharmacology
Published: March 12, 2025
Nectin-4: A promising prognostic marker and therapeutic target in cancer.
Journal: International review of cell and molecular biology
Published: February 12, 2025
Targeting mTOR and Its Associated Signaling to Induce Cell Death in Breast Cancer Stem Cells.
Journal: Cell biology international
Published: February 11, 2025
The apoptotic and anti-proliferative effects of Neosetophomone B in T-cell acute lymphoblastic leukaemia via PI3K/AKT/mTOR pathway inhibition.
Journal: Cell proliferation
Published: August 11, 2024
Fatty acid synthase: A key driver of ovarian cancer metastasis and a promising therapeutic target.
Journal: Pathology, research and practice
Published: June 06, 2024
Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: April 01, 2024
H2AX: A key player in DNA damage response and a promising target for cancer therapy.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 14, 2024
Last Updated: 09/26/2026